![David Cosman](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David Cosman
Directeur/Membre du Conseil chez Aequus BioPharma, Inc.
Postes actifs de David Cosman
Sociétés | Poste | Début | Fin |
---|---|---|---|
Aequus BioPharma, Inc.
![]() Aequus BioPharma, Inc. Medical/Nursing ServicesHealth Services Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars. | Directeur/Membre du Conseil | 17/09/2009 | - |
Historique de carrière de David Cosman
Anciens postes connus de David Cosman
Sociétés | Poste | Début | Fin |
---|---|---|---|
Immunex Corp.
![]() Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Corporate Officer/Principal | - | 14/07/2009 |
AMGEN INC. | Directeur Technique/Scientifique/R&D | - | - |
Statistiques
Internationale
Etats-Unis | 4 |
Opérationnelle
Director/Board Member | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 3 |
Health Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
AMGEN INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Aequus BioPharma, Inc.
![]() Aequus BioPharma, Inc. Medical/Nursing ServicesHealth Services Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars. | Health Services |
Immunex Corp.
![]() Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Health Technology |
- Bourse
- Insiders
- David Cosman
- Expérience